Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Akebia (AKBA) Therapeutics and Innovative Renal Care announced the broad availability of Vafseo for the treatment of anemia due to chronic kidney disease, CKD, in dialysis patients across all IRC clinics. Innovative Renal Care, IRC, has implemented a standardized treatment protocol for Vafseo across its network of more than 230 dialysis centers in 28 states and Washington, D.C., making it available as a treatment option for patients who both meet the FDA-approved clinical criteria and have access through IRC’s care model. This supports expanded availability for a subset of the more than 16,000 patients under IRC’s care, based on eligibility and clinical appropriateness. Vafseo was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. The therapy became commercially available in the U.S. in January 2025.